Kt Corporation ADR Stock
?
Your prediction
Financial data and news for KT
sharewise wants to provide you with the best news and tools for KT, so we directly link to the best financial data sources.
Financials
News
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- Kymera said its lead program KT-621 remains on schedule in Phase IIb trials for atopic dermatitis and
KT Q1 Earnings Call Highlights
KT (NYSE:KT) reported lower first-quarter earnings for fiscal 2026 as higher sales and labor costs and a year-earlier property development
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch
NAN FUNG TRINITY Loads Up KT Corp Stock With 1.49 Million Shares Bought
On February 3, 2026, NAN FUNG TRINITY (HK) LTD disclosed a new position in KT (NYSE:KT).
According to a recent SEC filing dated February 3, 2026, NAN FUNG TRINITY (HK) LTD initiated a new position